Your signal. Your price.
The FDA recently rejected MDMA-assisted psychotherapy due to concerns over placebo controls and therapist misconduct. Despite this setback, clinical trials showed that standard doses of MDMA resulted in clinical remission for up to 70 percent of PTSD patients.
Severe staff cuts at the FDA and CDC under Donald Trump's administration have coincided with an unprecedented wave of food safety recalls. Consumers face systemic risks, with glass, metal, and salmonella frequently slipping past weakened inspection regimes.
Brigham Buhler lobbied against the FDA decision to restrict 17 peptides, arguing it unnecessarily drives patients to unsafe gray markets. A massive retrospective analysis of 16 million BPC-157 patients revealed only three adverse events.
Only 3 results for these filters — try broadening your search